ArticleJournal of clinical laboratory analysis2025
Prognostic Value of a Novel Model for Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization.
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) patients who underwent transarterial chemoembolization (TACE) have heterogeneous clinical outcomes. Accurate prognosis prediction and risk stratification are crucial for individualized treatment. We sought to develop a novel prognostic model for overall survival (OS) that incorporated contemporary clinical and laboratory factors for estimating individual prognosis.
methodsA total of 180 HCC patients treated with TACE were used to identify the risk factors and generate prognostic models by Cox regression analyses. Model performance was evaluated by comparing it with the Tumor-Node-Metastasis (TNM) and Barcelona-Clinic Liver-Cancer (BCLC) staging systems.
resultsA prognosis model (PI score), which consisted of neutrophil-lymphocyte ratio (NLR), γ-glutamyl transpeptidase (GGT), alpha-fetoprotein (AFP), and TNM stage, was constructed. The PI scores of each patient were calculated, and the patients were divided into subgroups based on their PI scores. The OS rate of patients in the low-risk group (PI < 0.87) was better than that of the patients in the high-risk group (PI ≥ 0.87), p < 0.001. Patients were then further divided into four stages: early stage (PI ≤ 0.49), middle stage (0.49 < PI ≤ 0.87), advanced stage (0.87 < PI ≤ 1.48), and end stage (PI > 1.48). There were statistically significant differences between the OS rates of the four groups (p < 0.001). The area under the ROC curve (AUROC) for PI score (0.746, 0.643-0.783) was higher than those of TNM (0.699, 0.620-0.763) and BCLC (0.692, 0.617-0.760).
conclusionsThe PI score had excellent predictive value for HCC patients undergoing TACE and was superior to TNM and BCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.